Pharmaceutical

Drug manufacturers have a legal and ethical obligation to ensure their products are thoroughly tested for safety and effectiveness before reaching the market. While FDA approval is required for drug release, compliance with regulatory standards does not shield pharmaceutical companies from liability when they fail to warn the public about serious risks and side effects.

When known dangers are concealed or downplayed, patients can suffer severe and sometimes irreversible health consequences—including heart complications, liver damage, cancer, birth defects, and death.

Suboxone Tooth Loss Litigation

• Drug: Suboxone (buprenorphine/naloxone)
• Allegations: Prolonged use of Suboxone film is alleged to cause severe tooth decay, infections, and tooth loss due to its acidity and sublingual delivery method.
• Status: Active litigation. Attorney Meghan Connolly of Lowe Trial Lawyers serves on the Plaintiffs’ Steering Committee in this national mass tort.
• Injuries: Tooth decay, loss of teeth, jaw infections, and oral surgeries.

Ozempic / Wegovy / Mounjaro – GLP-1 Drugs Litigation

• Drugs: Ozempic, Wegovy, Mounjaro (semaglutide, tirzepatide)
• Allegations: These diabetes and weight loss drugs have been linked to gastroparesis (stomach paralysis), severe nausea, vomiting, and other gastrointestinal complications.
• Status: MDL (multidistrict litigation) formed in Pennsylvania.
• Injuries: Severe GI dysfunction, hospitalization, chronic digestive issues.

Depo-Provera and Meningioma Litigation

• Drug: Depo-Provera (medroxyprogesterone acetate)
• Allegations: Prolonged use of Depo-Provera, an injectable contraceptive, has been linked to the development of meningiomas—tumors that form on the membranes surrounding the brain and spinal cord. Studies suggest a heightened risk, particularly with long-term use or high cumulative exposure.
• Status: Emerging litigation. Several lawsuits have been filed against Pfizer, the drug’s manufacturer, alleging failure to warn about the risk.
• Injuries: Meningioma (benign or malignant), brain surgery, neurological symptoms, seizures, memory loss, and permanent disability.

Oxbryta and Sickle Cell Complication Litigation

• Drug: Oxbryta (Voxelotor)
• Allegations: Oxbryta was approved by the FDA in 2019 to treat sickle cell disease by preventing red blood cell sickling and improving hemoglobin levels. However, in September 2024, the drug was voluntarily withdrawn from the market by Pfizer after post-marketing data revealed a potential increase in severe complications, including vaso-occlusive crises, organ damage, and death. Plaintiffs allege that the manufacturer failed to adequately warn patients and healthcare providers about these life-threatening risks.
• Status: Emerging litigation. Lawsuits are anticipated on behalf of patients who experienced severe or fatal complications after taking Oxbryta.
• Injuries: Vaso-occlusive crises, stroke, kidney failure, worsening of sickle cell symptoms, and death.

At Lowe Trial Lawyers, our experienced pharmaceutical liability attorneys stand up to powerful drug manufacturers who put profit ahead of patient safety. We investigate cases involving inadequate warnings, misleading marketing, and dangerous drug formulations, fighting for full and fair compensation for those harmed.